MCL1 and metastatic neoplasm: In principle, a combination of a BH3 mimetic, such as BI-97D6 with more pronounced Bcl-2/Mcl-1 inhibitory activity, with a CRCA such as Ad.tCCN1-CTV-m7 expressing a systemically active cytokine, mda-7/IL-24 [62-64], should elicit profound efficacy toward both primary and metastatic tumors in the clinic.